Key clinical point: The biologic drug anakinra may be helpful in children with secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome, especially patients with underlying systematic juvenile idiopathic arthritis.
Major finding: Initiation of anakinra within 5 days was seen associated with lower mortality (P = .046).
Study details: A retrospective cohort study of 44 children with secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome and several different underlying diseases.
Disclosures: Two coinvestigators reported financial relationships with the maker of the study drug.
Eloseily E et al. Arthritis Rheumatol. 2019 Sep 12. doi: 10.1002/art.41103.